Friday, January 30, 2026

Biosimilars No Longer Second-Best: Highlighting Cost Savings and Improved Patient Access

Biosimilars are becoming standard care, with growing confidence in their safety and efficacy, driven by cost savings and improved accessibility.

Global Tensions Rise as North Korean Missiles Surface in Ukraine

A report from the U.S. DIA confirming Russia's use of North Korean ballistic missiles in its attack on Ukraine was released.

‘FUNDAMENTALLY EVIL’: Mike Pompeo Unleashes Scathing Attack On Kim Jong Un—Diplomacy Is DEAD

Pompeo suggests Kim Jong Un would seek sanctions relief at a summit, but believes chances for progress are virtually zero.

Tag: Eli Lilly

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

Eli Lilly vs. Novo Nordisk: A $1.2 Billion Bet Reveals Two Very Different Futures for Obesity Drugs

Eli Lilly and Novo Nordisk are pursuing different strategies in the obesity treatment market, focusing on expansion versus core strengths.

Nvidia and Eli Lilly: How AI is Revolutionizing Drug Development in 2026

Nvidia partners with Eli Lilly to enhance AI in drug development, aiming to revolutionize the biotech industry.

Rising Use of GLP-1 Drugs May Be Linked to Rare Pancreatitis Cases, Study Finds

Reports of acute pancreatitis linked to GLP-1 diabetes drugs surge in the UK, prompting investigations and conflicting academic findings.

Ozempic Maker Swaps CEO, Bets $2.2B on New Obesity Drug Fight

Novo Nordisk's leadership change aims to reclaim its obesity treatment market share amid competition from Eli Lilly's Mounjaro.

New Study: Mounjaro Helps Users Drop Over 50 Pounds

Eli Lilly's Mounjaro leads U.S. obesity drug market, outperforming semaglutide in weight loss efficacy and safety.

Novo Nordisk Pushes for First Oral Obesity Drug Approval

Novo Nordisk seeks FDA approval for oral Wegovy, potentially the first oral obesity treatment, amid competition with Eli Lilly.

Eli Lilly’s Oral GLP-1 Shows 7.9% Weight Loss in Type 2 Diabetes Trial

Eli Lilly's orforglipron shows promise in Phase 3 trials for diabetes and obesity, offering an oral alternative to injectables.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.